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Research Article
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We show here that the M2 isoform of human pyruvate kinase (M2PYK) is susceptible to
nitrosation and oxidation, and that these modiﬁcations regulate enzyme activity by pre-
venting the formation of the active tetrameric form. The biotin-switch assay carried out
on M1 and M2 isoforms showed that M2PYK is sensitive to nitrosation and that Cys326
is highly susceptible to redox modiﬁcation. Structural and enzymatic studies have been
carried out on point mutants for three cysteine residues (Cys424, Cys358, and Cys326)
to characterise their potential roles in redox regulation. Nine cysteines are conserved
between M2PYK and M1PYK. Cys424 is the only cysteine unique to M2PYK. C424S,
C424A, and C424L showed a moderate effect on enzyme activity with 80, 100, and
140% activity, respectively, compared with M2PYK. C358 had been previously identiﬁed
from in vivo studies to be the favoured target for oxidation. Our characterised mutant
showed that this mutation stabilises tetrameric M2PYK, suggesting that the in vivo resist-
ance to oxidation for the Cys358Ser mutation is due to stabilisation of the tetrameric
form of the enzyme. In contrast, the Cys326Ser mutant exists predominantly in mono-
meric form. A biotin-switch assay using this mutant also showed a signiﬁcant reduction
in biotinylation of M2PYK, conﬁrming that this is a major target for nitrosation and prob-
ably oxidation. Our results show that the sensitivity of M2PYK to oxidation and nitrosation
is regulated by its monomer–tetramer equilibrium. In the monomer state, residues (in par-
ticular C326) are exposed to oxidative modiﬁcations that prevent reformation of the active
tetrameric form.
Introduction
The Warburg effect is a frequent hallmark of cancer cells and describes the increased rate of glucose
uptake and consequent aerobic glycolysis to produce ATP and lactate [1]. Proliferating cells eschew
the standard oxidative phosphorylation pathway in favour of fermentation (even when oxygen is avail-
able), a process that may allow more efﬁcient production of metabolite building blocks via glycolysis
at the expense of more efﬁcient ATP production in the mitochondria [2].
Pyruvate kinase (PYK) catalyses the ﬁnal step of glycolysis and transfers a phosphoryl group from
phosphoenolpyruvate (PEP) to ADP to produce pyruvate and ATP [3]. There are four pyruvate
kinase isoforms in humans that are expressed in different tissue environments. Liver PYK (LPYK) is
found in tissues where gluconeogenesis is carried out, primarily in the liver, but also in kidney and
intestine [4]. Erythrocyte PYK (RPYK) is exclusively found in red blood cells and is very similar to
LPYK, both enzymes being expressed from the same gene (PKLR) under the control of different
tissue-speciﬁc promoters [5]. M1PYK and M2PYK are produced from the PKM gene by mutually
exclusive alternative splicing; exons 9 and 10 are speciﬁc to M1- and M2PYK, respectively, while all
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other exons are common to both isoforms [6]. M1PYK is a highly active, non-allosteric isoform that is
expressed in tissues where large amounts of ATP need to be produced rapidly, such as brain and muscle [7].
M2PYK is expressed in all proliferating cells and is a tightly controlled allosteric enzyme.
The result of mutually exclusive splicing of the PKM gene transcript is that M1- and M2PYK differ in 22
residues within a 56 residue region situated at the C–C interface, where the C-domains of each monomer
interact to form the PYK tetramer (Figure 1) close to the binding site for fructose 1,6-bisphosphate
(F-1,6-BP), the allosteric activator of M2-, L-, and RPYK [6]. These differences alone allow M2PYK to exist
in an allosterically regulated tetramer : dimer : monomer equilibrium while M1PYK is held in a constitu-
tively active tetrameric state [8,9]. Comparison of the crystal structures of M1PYK and M2PYK bound to
ATP, oxalate, and F-1,6-BP shows an overall r.m.s ﬁt of ∼0.5 Å with the only signiﬁcant difference being
seen in the splice variant region [9].
M2PYK exists in a concentration-dependent tetramer : dimer : monomer equilibrium with a Kd for tetramer
dissociation likely to be in the low micromolar range [9,10]. At sub-Kd concentrations, M2PYK dissociates into
monomers that are inactive [9]. The tetramer dissociation rate is slow with a half-life of ∼15 min [10]. Small
molecule allosteric activators and inhibitors have also been characterised: F-1,6-BP activates M2PYK by stabilis-
ing the tetrameric form of M2PYK in the R-state, while the inhibitory amino acids phenylalanine, tryptophan,
and alanine bind in a different allosteric pocket and stabilise the inactive T-state tetramer [9,10].
M2PYK regulation is complex; its activity has been found to be inﬂuenced by more than 30 naturally occur-
ring metabolites. Inhibitors include phenylalanine, thyroid hormone triiodo-L-threonine (T3), tryptophan,
alanine, oxalic acid, and ribose 5-phosphate [9,10]. Phenylalanine and alanine have also been identiﬁed as inhi-
bitors of M2PYK in rat and mouse [11–13]. In addition, tryptophan has been found to be an inhibitor of rat
M2PYK [13]. In an extensive study of metabolite activators and inhibitors, no M1PYK activators were identi-
ﬁed and only phenylalanine and oxalic acid were identiﬁed as weak inhibitors; in contrast, for M2PYK 14 acti-
vators were identiﬁed, with F-1,6-BP, histidine, and serine being the strongest [9,14]. F-1,6-BP has been
identiﬁed as an allosteric activator of PYK in most organisms (e.g. Escherichia coli [15], globeﬁsh [16], and
mammals [9]); however, exceptions include mycobacteria and Toxoplasma PYK which are activated by glucose
6-phosphate and AMP [17,18] and protist kinetoplastid PYK including that of the parasite Leishmania which
is activated by fructose 2,6-bisphosphate (F-2,6-BP) [19].
Oxidation has also been implicated as a mechanism for inhibiting PYK orthologues including the yeast,
E. coli, and human enzymes [20–22]. A study carried out using A549 human lung cancer cells found that an
increase in intracellular reactive oxygen species (ROS) concentrations leads to decreased M2PYK activity [23].
This inhibition was reversed after the treatment of cell lysates with the reducing agent dithiothreitol (DTT). It
Figure 1. Allosteric regulation of M2PYK activity occurs through changing the tetramer–monomer equilibrium.
(A) Architecture of the M2PYK tetramer. Chain A has been coloured to help to identify the different domains; N (cyan = residues
1–25), A (red = residues 25–116 and 220–402), B (blue = residues 117–219), and C (yellow = residues 403–531). The large (A–A)
and small (C–C) interfaces are indicated by the dashed lines. The active site and effector site have been highlighted by red
boxes. (B) M2PYK catalyses the ﬁnal step of the glycolytic pathway, converting PEP to pyruvate and producing ATP. M2PYK
exists in an oligomeric equilibrium between inactive monomer/dimer and active tetramer states. Activators, such as
fructose-1,6-BP, promote the active tetramer state. Allosteric inhibitors, oncoproteins, and post-translational modiﬁcations
(PTMs) have been found to promote the inactive monomer/dimer state.
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was proposed that oxidation of M2PYK leads to dissociation of the homotetramer, a conclusion based on the
observation that treatment of human lung cancer cells expressing FLAG-tagged M2PYK with the oxidising
agent diamide prevented tagged M2PYK co-immunoprecipitating with endogenous M2PYK [23]. The signiﬁ-
cance of this for the cancer cells is explained by the authors in a model in which the regulation of M2PYK by
the redox potential of the cell allows cancer cells to sustain antioxidant responses [23]. The idea is that inhib-
ition of M2PYK would lead to accumulation of the glycolytic intermediate glucose 6-phosphate, which would
then increase its entry into the pentose-phosphate pathway (PPP) thereby producing NADPH which is used by
glutathione reductase (GR) to convert oxidised glutathione (GSSG) to reduced glutathione (GSH). This would
have the effect of decreasing the oxidising potential of the cell and allowing oxidation of M2PYK to be reversed,
leading to reactivation of the enzyme.
Here, we examine the effects of redox level on the oligomeric state and enzymatic activity of recombinant
wild-type (WT) human M2PYK and many mutants with Cys-to-Ser mutations. We also show that
S-nitrosation as well as oxidation regulate M2PYK oligomeric state and enzymatic activity. The evidence is also
presented that stabilisation of the M2PYK tetramer can protect it from oxidation.
Experimental
Cloning of M2PYK mutants
Mutants of M2PYK were made using the QuikChange site-directed mutagenesis kit (Stratagene) using
pET28a-M2PYK as a template and following the instructions in the manual. The following mutants were gen-
erated: C31A, C326S, C358A, C358S, C423S, C424A, C424S, and C424L. Mutations were conﬁrmed by
sequencing.
Expression of human MPYKs in E. coli
The following procedure was used to express M2PYK WT, M1PYK WT, and all M2PYK mutants, except
M2PYK C326S. Mutated plasmids were used to transform chemically competent E. coli BL21 cells (Novagen).
Single colonies were used to inoculate 50 ml of LB media containing 50 mg/ml kanamycin and incubated at 37°C
overnight with shaking. A total of 10 ml of cultures were taken from each of the overnight cultures and used to
inoculate 1 l of 2xTY media containing 50 mg/ml kanamycin. In total, 1 l of cultures were grown to an OD600
of 0.8 at 37°C with shaking. Cultures were incubated at 4°C for 20 min before inducing expression by adding
isopropyl-β-D-thiogalactopyranoside (IPTG) to a ﬁnal concentration of 1 mM and incubating at 20°C for 18 h
with shaking. Cells were harvested in a JLA-8.1000 rotor at 15 970×g for 20 min at 10°C. Pellets from 1 l of cell
cultures were ﬂash frozen in liquid nitrogen before being stored at −80°C.
For expression of M2PYK C326S, the mutated plasmid was used to transform chemically competent
E. coli BL21 star cells (Novagen). A single colony was used to inoculate 50 ml of LB medium containing
50 mg/ml kanamycin and incubated at 37°C overnight with shaking. Approximately 10 ml was taken from
the overnight culture and used to inoculate 1 l of LB medium containing 50 mg/ml kanamycin. This 1 l
culture was grown to an OD600 of 0.6–0.8 at 37°C with shaking. IPTG was added to a ﬁnal concentration of
1 mM to induce expression and the culture was incubated at 18°C for 3 h with shaking. Cells were harvested
in a JLA-8.1000 rotor at 15 970×g for 20 min at 10°C. Cell pellets (1 l) were ﬂash frozen in liquid nitrogen
before being stored at −80°C.
Preparation of cell lysates
All puriﬁcation steps were carried out at 4°C unless otherwise stated. Cell pellets from 1 l of cell culture were
resuspended in 30 ml of lysis buffer [50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, pH 8.0, with
EDTA-free protease inhibitors (Roche)]. Cells were lysed at 6°C by a single passage through a Constant Systems
Cell Disruptor (1.1 kW TS Benchtop) set at 22 kpsi, followed by centrifugation at 58 500 ×g for 45 min at 10°C,
and then the supernatant was ﬁltered through a 0.2 mm ﬁlter.
Puriﬁcation of bacterially expressed M PYKs
A clariﬁed cell lysate was loaded onto a 5 ml IMAC HiTrap HP Sepharose column pre-charged with cobalt at
2 ml/min. The ﬂow rate was maintained at 2 ml/min for the duration of the afﬁnity puriﬁcation step. The
column was washed with 12 column volumes (CVs) of buffer A (50 mM NaH2PO4, 300 mM NaCl, 20 mM
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 3277
Biochemical Journal (2018) 475 3275–3291
https://doi.org/10.1042/BCJ20180556
imidazole, pH 8.0) followed by an additional wash step with 15 CVs of 20% buffer B (50 mM NaH2PO4,
300 mM NaCl, 250 mM imidazole, pH 8.0) to wash off contaminating proteins. The His-tagged MPYK protein
was eluted using a 5 CV step gradient of 100% buffer B. Eluted fractions were pooled and concentrated with a
Vivaspin concentrator (molecular mass cut-off 30 kDa) before loading onto a HiLoad 16/600 Superdex 200
column gel ﬁltration column pre-equilibrated with Dulbecco’s phosphate-buffered saline without calcium and
magnesium (PBS-CM — Sigma Cat. No. D5652). A ﬂow rate of 1 ml/min was used throughout the gel ﬁltration
process. Eluted fractions were pooled and concentrated to ∼20 mg/ml using a Vivaspin column with a molecu-
lar mass cut-off of 30 kDa.
Measurement of protein concentration
Protein concentration was determined by measuring absorbance at 280 nm and the molar absorption coefﬁ-
cient ε280 nm = 28 600 M
−1 cm−1. Concentrated samples in PBS-CM were ﬂash frozen with liquid nitrogen and
stored at −80°C.
Measuring PYK activity using the lactate dehydrogenase-coupled assay
Protein solutions (5 ml) of 0.0025 mg/ml M PYK were prepared by dilution in PBS-CM (pH 7.4) with or
without the addition of additives. The protein solutions were incubated at room temperature for 3 h to ensure
oligomeric equilibrium was reached. Assay buffer comprised PBS-CM, 20 mM MgCl2, 200 mM KCl, 4 mM
ADP, 1 mM NADH, and 30 U/ml LDH (lactate dehydrogenase). Approximately 5 ml of 2× assay buffer was
taken and PEP added to a concentration of 10 mM. The ﬁnal mixture was re-adjusted to pH 7.4 after the add-
ition of compounds.
Two-fold serial dilutions of PEP were prepared in a 96-well master block (Greiner Bio-one Cat. No. 780270)
using 2× assay buffer for dilution yielding PEP concentrations ranging from 78 mM to 10 mM (ﬁnal assay con-
centrations 39 mM to 5 mM). A multi-channel pipette was used to transfer 50 ml of each PEP dilution to a
column of a 96-well plate (Greiner Bio-one Cat. No. 655101).
The reaction was started by adding 50 ml of protein solution to the PEP titrations in the 96-well plate using
a multi-channel pipette. Final concentrations of reagents were as follows: 0.00125 mg/ml M PYK, 10 mM
MgCl2, 100 mM KCl, 2 mM ADP, 15 U/ml LDH, 0.5 mM NADH, and PEP concentrations ranging from
39 mM to 5 mM.
The assay solutions and protein solutions were pre-incubated at 37°C for 10 min before mixing together.
Plates were agitated for 10 s before measuring the decrease in absorbance at 340 nm for 5 min using a plate
reader which was set at 37°C (SpectraMax M5 multimode plate reader, Molecular Devices). Initial reaction
rates were obtained using the SoftMax Pro software. Substrate-velocity graphs were plotted using Kaleidograph
(Synergy Software).
Measuring PYK activity using the Kinase Glo assay
Protein solutions (5 ml) of 0.0025 mg/ml M1PYK or M2PYK were prepared by diluting in PBS-CM and were
incubated at room temperature for 3 h with either 10 mM H2O2 or with 1 mM DTT to ensure oligomeric equi-
librium was reached. Assay buffer comprised: PBS-CM, 20 mM MgCl2, 200 mM KCl, and 4 mM ADP. About
5 ml of 2× assay buffer was taken and PEP added to a concentration of 2 mM and then transferred to a 96-well
plate (Greiner Bio-one Cat. No. 655101). The reaction was started by adding 25 ml of protein solution to the
PEP solution in the 96-well plate using a multi-channel pipette. The ﬁnal concentrations of the reagents were
as follows: 0.00125 mg/ml M PYK, 10 mM MgCl2, 100 mM KCl, 2 mM ADP, and 1 mM PEP. The reaction
was incubated for 30 min before adding 50 ml of Kinase Glo Plus reagent (Promega) and incubated at room
temperature in the dark for 10 min. Endpoint luminescence readings were measured using a SpectraMax M5
multimode plate reader at room temperature.
Dynamic light scattering
Mass distribution analysis of M2PYK mutant protein solutions by dynamic light scattering was performed on a
Zetasizer APS (Malvern Instruments) with ﬁve repeat runs of 60 μl (1 mg ml−1) in PBS-CM, at 22°C, with a
120-s equilibration.
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Thermal shift assay
The SYPRO Orange dye is supplied by Invitrogen (catalogue no. S6650) at 5000× concentration in DMSO and
was diluted in PBS-CM before use. Test samples were prepared in a 96-well PCR plate (Bio-Rad) before adding
SYPRO Orange dye and sealing the plate with optical quality tape (Bio-Rad). Each 50 ml sample contained
0.55 mg/ml protein in PBS-CM with 1.11 mM F-1,6-BP, 1 mM H2O2, or 1 mM DTT. The 96-well plate was
heated in an i-Cycler iQ5 real-time PCR detection system (Bio-Rad) from 20 to 80°C in increments of 1°C. A
charge-coupled (CCD) camera was used to monitor the ﬂuorescence changes in the wells simultaneously using
an excitation wavelength of 485 nm and an emission wavelength of 575 nm.
Analytical size-exclusion chromatography
Analytical size-exclusion chromatography was carried out as described previously [9]. M1- and M2-PYK
protein samples were incubated overnight at room temperature at 0.1 mg/ml before loading independently onto
a calibrated Superdex 200 PC 3.2/30 gel ﬁltration column (GE Healthcare), with a total bed volume of 2.38 ml,
pre-equilibrated in PBS-CM at room temperature, and run at 0.1 mg/ml. To ensure loading consistency
between runs, a 25 ml loop was ﬁlled with 50 ml of the sample, followed by a run load-volume of 50 ml. UV
absorbance was monitored at both 280 and 214 nm, with a 10 mm path length ﬂow-cell.
In vitro biotin-switch assay
In vitro biotin-switch assay was carried out for the identiﬁcation of S-nitrosated proteins. Protein samples (pre-
incubated with or without 1 mM F-1,6-BP or 4 mM phenylalanine) were prepared by diluting to a concentra-
tion of 0.17 mg/ml in HEN buffer (250 mM HEPES, 1 mM EDTA, 0.1 mM neocuproine, pH 7.7). CysNO was
used as the NO donor and was prepared by mixing 20 ml of 100 mM L-cysteine (dissolved in 200 mM HCl)
with 20 ml of 100 mM NaNO2 (dissolved in H2O) resulting in 50 mM solution of CysNO, which was then
added to protein samples to a ﬁnal concentration of 1 mM for protein S-nitrosation. The reaction was incu-
bated in the dark for 20 min at room temperature. The addition of 0.1% SDS for exposing all cysteine residues
was used as a positive control. No CysNO was added for the negative control sample.
After incubation, CysNO donor was removed by passing the samples through pre-equilibrated Zeba-spin
columns. NEM (N-ethylmaleimide)-blocking buffer (HEN buffer, 5% SDS, and 50 mM NEM) was added to
unfold the protein and block all unmodiﬁed cysteines, and the reaction was incubated at 50°C for 30 min. Two
volumes of −20°C 100% acetone were then added and the samples were incubated at −20°C for 20 min.
Precipitated protein was pelleted by centrifuging at 14 000×g for 5 min at 4°C. The supernatant was removed.
The protein pellet was washed three times with −20°C 70% acetone. Residual acetone was allowed to evaporate
by placing tubes uncapped in the dark at room temperature.
Protein pellets were resuspended in 85 ml of HENS buffer (HEN buffer with 1% SDS). Biotin-labelling solu-
tion (ﬁnal concentration: 25 mM ascorbate and 0.4 mM biotin-HPDP) was added and the samples were incu-
bated for 1 h at room temperature. In this step, any nitrosated cysteine can be reduced by ascorbate and thus
biotinylated by biotin-HPDP. Non-nitrosatable cysteines were blocked by NEM and thus not biotinylated. After
biotinylation, proteins were collected by acetone precipitation again: two volumes of −20°C 100% acetone were
then added and the samples were incubated at −20°C for 20 min. Precipitated protein was pelleted by centrifu-
ging at 14 000×g for 5 min at 4°C. The supernatant was removed. The protein pellet was washed for three
times with −20°C 70% acetone. Residual acetone allowed to evaporate by placing tubes uncapped in dark at
room temperature.
Each protein pellet sample was resuspended with 300 ml HENS buffer (25 mM HEPES, 1 mM EDTA, 1 mM
neocuproine, and 1% SDS). Twenty microlitres per each sample were taken out as an ‘input’ control. For each
of the rest 280 ml sample, 1.5 ml of neutralisation buffer (25 mM HEPES, 100 mM NaCl, 1 mM EDTA, and
0.5% Triton X-100, pH 7.5) and 20 ml of streptavidin beads were added to pull-down the biotinylated (i.e.
S-nitrosated) proteins.
After an overnight incubation at 4°C, streptavidin beads conjugated with biotinylated proteins were centri-
fuged down 30 s at 2200 ×g. Unbound proteins were removed by ﬁve times washing with neutralisation buffer.
Biotinylated samples were eluted using buffer containing 1% β-mercaptoethanol (each sample was incubated
with 20μl of elution buffer for 30 min at room temperature).
After an SDS–PAGE was run for each eluted sample, the protein bands were transferred onto a nitrocellulose
membrane at 80 V at 4°C for 90 min for further western blot analysis. The membrane was blocked with PBST
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Biochemical Journal (2018) 475 3275–3291
https://doi.org/10.1042/BCJ20180556
(PBS with 0.05% Tween 20) supplemented with 5% skimmed milk powder at room temperature for 1 h. The
blocked membrane was then incubated with 1 : 2000 diluted HRP-linked anti-His-tag antibody overnight at 4°C.
After the membrane was washed three times with PBST with 5% skimmed milk powder followed by twice with
PBS, ECL solutions were applied for luminescence exposure.
Crystallisation screening procedures
Puriﬁed M2PYK C358A, M2PYK C358S, and M2PYK C424A samples that had been stored at −80°C were
used for the experiments. Proteins were thawed on ice before mixing with ligands. Crystallisation experiments
were carried out by the vapour diffusion method and the hanging drop technique at 18°C (M2PYK C424A) or
4°C (M2PYK C358S).
Crystallisation drops were set up by mixing 1.5 ml of well solution with 1.5 ml of 10 mg/ml protein sample
containing 5 mM of each ligand [9]. The well solution consisted of 6–16% PEG 3350, 100 mM sodium cacody-
late (pH 6), 20 mM triethanolamine–HCl buffer (pH 7.2), 50 mM MgCl2, and 100 mM KCl. The drops were
equilibrated against 1 ml of well solution.
Data collection and processing
X-ray intensity data from crystals were collected at the Diamond synchrotron radiation facility in Oxfordshire,
U.K. on beamline IO2. Prior to data collection, crystals were equilibrated over a well solution containing a high
concentration of PEG-3350 to help dehydrate the crystal and eliminate the appearance of ice-rings. The inten-
sity data were collected from single crystals ﬂash frozen in liquid nitrogen at 100 K. Processing was carried out
by the Xia2 automated data reduction system.
Model building and reﬁnement
The M2PYK C358S structure was solved by molecular replacement using MolRep [24] using the AC domains
of the M2PYK structure with PDB ID: 3SRH. Because the B-domains of the M2PYK C358S structure have very
poor density, they were solved separately. One of the B-domains was found by using a B-domain of M2PYK
3SRH separately in MolRep reﬁnement. The other three B-domains were placed by ﬁnding the corresponding
B-domains in the rabbit M2PYK structure with PDB ID: 1PKN. The structure was then reﬁned using
REFMAC5 [25]. The M2PYK C424A structure was solved by molecular replacement using MolRep. The
M2PYK structure with PDB ID: 3SRD was used as the search model because the two crystals are isomorphous.
The structure was then reﬁned using REFMAC5.
Results and discussion
Redox level regulates the stability, oligomeric state, and enzymatic activity of
M2PYK
Oxidising conditions favour monomeric M2PYK
Analytical gel ﬁltration was used to investigate the effect of oxidation on the oligomeric state of M2PYK. A
stock solution of M2PYK (∼20 mg/ml) was diluted to 0.1 mg/ml in PBS-CM and then incubated in the pres-
ence and absence of DTT or H2O2 at room temperature for 1 h (Figure 2A) and 12 h (Figure 2B) before inject-
ing onto a Superdex 200 PC 3.2/3.0 gel ﬁltration column pre-equilibrated in PBS-CM. The two major peaks
run with identical elution volumes as those previously identiﬁed using size-exclusion multi-angle scattering as
tetramers and monomers with absolute molar masses of 214 and 53 kDa, respectively [9]. A series of analytical
gel ﬁltration runs have been used to show that M2PYK dissociates over time until an equilibrium between
tetramer and monomer is reached (Figure 2, blue lines). The tetramer–monomer dissociation Kd is estimated
to be ∼0.9 μM with an apparent dissociation rate with t1/2 ∼ 15 min [10]. After incubation at the lower con-
centration for 1 h [following dilution from ∼350 mM (20 mg/ml) to ∼1.7 mM (0.1 mg/ml)], a small effect on
the monomer tetramer distribution can be observed (Figure 2A). The difference after 12 h once equilibrium
had been reached is marked: DTT maintained the majority of M2PYK as tetramers, whereas incubation with
H2O2 clearly shifted the equilibrium towards a higher proportion of monomers (Figure 2B). These experiments
are therefore consistent with the conclusion that a reducing environment promotes tetramerisation of M2PYK,
while oxidation promotes dissociation. The similarity in Figure 2 between control M2PYK (measured under
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ambient conditions) and the H2O2-treated enzyme suggests that the oxidising effects of air also signiﬁcantly
affect the M2PYK oligomeric state.
Oxidising conditions decrease the thermostability of M2PYK
To determine the effect of oxidising conditions on the stability of M2PYK, a thermal shift assay was carried
out in the presence of 1 mM DTT or 1 mM H2O2. DTT (1 mM) or H2O2 was added to 0.55 mg/ml M2PYK
before the addition of the SYPRO Orange environmentally sensitive dye and measurement of ﬂuorescence
using a real-time PCR detection system as it heated the samples in increments of 1°C from 20 to 80°C
(Figure 3).
Figure 2. Effects of redox environments on the oligomerisation of M2PYK.
M2PYK stock solution of ∼20 mg/ml was diluted to 0.1 mg/ml in PBS-CM and incubated, in the absence and presence of
1 mM DTT or 20 μM H2O2, at room temperature for (A) 1 h and (B) 12 h before injecting a 25 ml sample into a Superdex® 200
PC 3.2/30 gel ﬁltration column pre-equilibrated in PBS-CM. Assuming a bimodal tetramer (T): monomer (M) distribution, the
peak areas correspond to:
M2PYK (DTT,  H2O2) at 1 h (62% T, 38% M) and at 12 h (55% T, 45% M)
M2PYK (DTT, + H2O2) at 1 h (63% T, 37% M) and at 12 h (42% T, 58% M)
M2PYK (þDTT,  H2O2) at 1 h (64% T, 36% M) and at 12 h (71% T, 29% M):
Figure 3. Thermal stability of M2PYK and the effects of redox environments.
Thermal denaturation data for M2PYK (ﬁnal concentration 0.49 mg/ml) in the presence of 1 mM DTT (green), 1 mM H2O2 (blue),
or with no additives (red). RFU, relative ﬂuorescence units; −d(RFU)/dT, negative derivative of RFU.
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Incubation of M2PYK with DTT resulted in a slight increase in melting temperature (Figure 3), indicating
that the reducing conditions stabilise the structure of M2PYK, but not to the extent as achieved by the allosteric
activator F-1,6-BP which increases the melting temperature by ∼7°C [9]. In contrast, the presence of H2O2
causes a signiﬁcant decrease in Tm of 5°C, showing that oxidising conditions have a destabilising effect on
M2PYK structure (Figure 3). Thermostability of M1PYK is not affected by either oxidising or reducing condi-
tions, thus showing that the observed effect on M2PYK is not simply a non-speciﬁc effect of redox conditions
on protein structure.
Oxidising conditions decrease the enzymatic activity of M2PYK
The activity of M2PYK in the presence of 1 mM DTT or 10 mM H2O2 was measured in order to investigate
the effect of oxidising conditions on its activity. As a control, the activity of the constitutively active and tetra-
meric M1PYK was also measured. Before measuring the activity using the Kinase Glo assay kit, the M1PYK
and M2PYK proteins (0.0025 mg/ml) were incubated at room temperature for 3 h in order to allow oligomeric
equilibrium to be reached. The results show that oxidising conditions signiﬁcantly decrease the activity of
M2PYK when compared with reducing conditions, whereas there is little change in the activity of M1PYK
(Figure 4). The observation that M1PYK activity is unaffected by oxidising conditions provides additional
support to the hypothesis that the effect on M2PYK is speciﬁc, especially given the similarity in sequence and
overall structure between the two isoforms.
Reducing agents increase the enzymatic activity of M2PYK
The effect of DTT and GSH on the enzymatic activity of M2PYK is shown in Figure 5A. At saturating condi-
tions (∼ 100 mM), both reducing agents increase the speciﬁc activity by ∼4-fold. The fact that both GSH and
DTT showed activating effects suggests that activation is due to the reducing properties of DTT and GSH
rather than a speciﬁc ligand-binding effect.
We have previously shown that M2PYK acts as an amino acid nutrient sensor and is inhibited by Ala, Phe,
and Trp and activated by Ser [10]. Here, we show that this allosteric regulatory mechanism is further modu-
lated by oxidising or reducing conditions. IC50 values of L-alanine and L-phenylalanine increased by up to
10-fold in the presence of DTT (Figure 5B–D).
Figure 6A,B shows the combined effects of the inhibitor Ala with the activator Ser in the presence and
absence of the reducing agent DTT. The amino acids compete for the same allosteric site, so that the relative
concentrations of inhibitor/activator govern the degree to which M2PYK is activated [10]. Under reducing con-
ditions, the effect of the Ala inhibitor is lessened with an IC50 ∼124 mM compared with 45 mM with no DTT
present. Increasing Ser concentration further reduces the inhibitory effect of Ala which is expected as Ala and
Ser compete for the same allosteric site. A similar effect is observed for Phe and Ser (Figure 6C,D), where the
IC50 for the inhibitor Phe is increased from 57 to 410 mM in the presence of 1 mM DTT. As with Ala, there is
an increase in the IC50 of Phe as the Ser concentration increases. These IC50 changes show that the activation
Figure 4. The enzymatic activity of M2PYK is signiﬁcantly decreased in oxidising conditions.
The Kinase Glo assay was used to measure the activity of M1PYK and M2PYK (0.0025 mg/ml) in the presence of 1 mM DTT
(reducing conditions) or 10 mM H2O2 (oxidising conditions).
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of M2PYK under reducing conditions complements the binding of the activating Ser but antagonises binding
of the inhibitory amino acids Phe and Ala. X-ray structures of active R-state (Ser-bound) M2PYK tetramers
have a different conformation to the Phe/Ala-bound T-state [9,10]. The activity results are therefore consistent
with reducing agents favouring an R-state conformation which disfavours Ala or Phe ﬁtting in the allosteric
amino acid-binding pocket.
The role of Cys residues in M2PYK redox regulation
Ten cysteines are found in the sequence of M2PYK (i.e. 1.9% of the amino acid composition) (Figure 7). A
cysteine content of 1.9% is about average for a mammalian intracellular protein, which is typically 2.2% [26].
Many of the cysteines of M2PYK are readily accessible to solvent and thus modiﬁcation by oxidising agents,
suggesting that regulation of M2PYK by oxidation may be complex and involve multiple cysteines.
Effect of mutations on the C–C interface: C424S, C424A, and C424L
M2PYK C424 is the only cysteine unique to M2PYK, with the equivalent residue in M1PYK being a leucine.
This cysteine is situated within the splice variant region at the C–C interface, where the C-domains of each
monomer interact to form the PYK tetramer. The splice variant region encodes residues 378–434, and within
this region, only 22 amino acids differ between the constitutively active M1PYK and the allosteric M2PYK
(Figure 7). We have made point mutations in M2PYK by site-directed mutagenesis to create M2PYK C424S,
M2PYK C424A, and M2PYK C424L.
A thermal shift assay was carried out to compare the thermal stability of the M2PYK C424 point mutants
with that of M1PYK and M2PYK WT enzymes in oxidising and reducing conditions. Mutants in which C424
has been replaced with a hydrophobic residue, C424A and C424L, have very similar thermal stability as
Figure 5. Reducing agent affects the enzymatic activity of M2PYK and its sensitivity to amino acid inhibitors.
(A) Reducing agents increased the enzymatic activity of M2PYK. The titrations of DTT and GSH showed that the enzymatic
activity of M2PYK is redox-dependent. (B) The inhibitory effect of L-alanine on the enzymatic activity of M2PYK was regulated
by DTT. (C) The inhibitory effect of L-phenylalanine on the enzymatic activity of M2PYK was regulated by DTT. (D) The
presence of DTT desensitised M2PYK to the inhibitory effects of free amino acids. The IC50 values of amino acid inhibitors
were signiﬁcantly increased by the addition of DTT (present in B, C, and D at a concentration of 100 mM). Data represent the
mean ± SEM of three independent experiments.
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M2PYK WT (data not shown). The hydrophilic mutation C424S, however, results in a decrease in thermal sta-
bility and a higher sensitivity to treatment with H2O2 (Figure 3) [27]. A decrease in stability with an increasing
hydrophilicity of cysteine-point mutants may explain the destabilisation of M2PYK in oxidising conditions
where hydrophilic sulfonate or sulﬁnate adducts are likely to be generated [28].
Figure 6. Competing and complementary effects of activator (Ser) and inhibitors (Ala, Phe) in the presence and absence of DTT.
(A) (left) Inhibitory effect of Ala in the presence of different concentrations of the activator Ser. (Right) bar chart shows how the IC50 for Ala increases
in the presence of increasing concentrations of Ser. (B) Same as (A) but in the presence of 1 mM DTT which signiﬁcantly reduces the afﬁnity for Ala.
(C) Same as (A) but with Phe rather than Ala. (D) Same as (C) but in the presence of 1 mM DTT which signiﬁcantly reduces the afﬁnity for Phe.
Figure 7. Positions of cysteines in M2PYK sequence and structure.
Left, sequence alignment of M1 and M2PYK showing positions of 10 cysteines (indicated by asterisks) and the 22 residues
that differ between M1 and M2PYK within the splice variant region. Right, a cartoon of M2PYK monomer showing the
positions of cysteines in the folded structure.
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Enzymatic activities of M2PYKC424S, M2PYKC424A, and M2PYKC424L were measured using the
LDH-coupled spectrophotometric assay. A summary of kinetic data for site point mutants and WT enzymes is
given in Supplementary Table S1. Velocity (absorbance units/s) values are presented in Figure 8 as percentages
of the M2PYK WT velocity. The activity of M1PYK was also measured as Cys424 is the only cysteine of
M2PYK that is not present in M1PYK. The results show that as the hydrophobicity by the mutation is
increased, the activity of the enzyme also increases, with M2PYK C424L having a similar activity to M1PYK in
the absence of the allosteric activator F-1,6-BP (Figure 8). These results ﬁt well with the thermal shift data,
showing that the less stable C424S mutant has a lower activity than M2PYK WT, while C424A has very similar
thermal stability and enzyme activity to WT and the C424L mutant is the most stable and is most active. These
results are in agreement with the results of Ikeda and Noguchi who found that the C424L mutation in rat
M2PYK resulted in increased activity and loss of allosteric regulation by F-1,6-BP [29].
M2PYK C424A was co-crystallised with F-1,6-BP, oxalate, and ATP and crystals diffracted to a maximum
resolution of 2.87 Å. A model of M2PYK WT (PDB code: 3SRD) was used to calculate the |Fo− Fc| difference
electron density map with M2PYK C424A. The difference electron density map gave a clear negative peak
where the cysteine has been substituted by alanine consistent with the C424A mutation (Supplementary
Figure S2). Superposition of the M2PYK C424A structure with that of the M2PYK WT holo structure (PDB
code: 3SRD) results in an overall RMS deviation of 0.57 Å. The maximum displacement between M2PYK WT
holo and M2PYK C424A is 3 Å which occurs at around residue 126 on each of the four chains. This difference
is caused by the B-the domain of the M2PYK C424A structure adopting a slightly more closed orientation
than in the M2PYK WT structure.
Characterisation of the C326S and C358S mutants
Cys326 is located at the A–A interface and is therefore completely buried in tetrameric M2PYK. However, in
the monomeric form, Cys326 is exposed to the solvent making it accessible to oxidising agents (Figure 1).
Cys358 is situated in the β-barrel close to the active site and its buried location makes it a surprising candidate
for modiﬁcation. It has, however, previously been identiﬁed as being important in the regulation of M2PYK by
oxidation [23]. We have made point mutations in M2PYK by site-directed mutagenesis to create M2PYK
C326S and M2PYK C358S.
It has been inferred from cellular studies that the enzymatic activity and the oligomeric state of M2PYK
depend on its redox state [23]. The suggestion that Cys358 was the main residue that was affected by oxidation
was based on the observation that the activity of the mutant M2PYK C358S is free from effects of reducing
agents or oxidants. However, as we have shown with the C424 mutants, the hydrophobicity of the side chain
can also have an effect on tetramer stability and factors other than oxidation of Cys358 may play a role in the
observed loss of activity.
Figure 8. Increasing the hydrophobicity of residue 424 increases M2PYK enzymatic activity.
Enzymatic activity was measured using the LDH-coupled assay with 0.00125 mg/ml M2PYK in the presence of 1 mM DTT and
saturating substrate concentrations (1 mM PEP and 2 mM ADP). Velocity values (in Abs units/s) were calculated and are
presented here as a percentage of the M2PYK WT velocity.
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We have carried out analytical gel ﬁltration of M2PYK C358S and show that the oligomerisation state of
M2PYK C358S has a higher proportion of tetramer compared with WT M2PYK (Figure 9). It is, therefore, pos-
sible that the in vivo effect observed by Anastasiou et al. was due to the protection of other cysteines (e.g.
Cys326 or Cys424), which are buried in the interfaces of the tetrameric PYK held stable by the C358S muta-
tion. Analytical gel ﬁltration of M2PYK C326S was also carried out and showed the striking result that this
mutation causes M2PYK to become predominantly monomeric (Figure 9 and Supplementary Figure S1). This
result supports the idea that oxidation of this C326 could play a major role in the regulation of M2PYK with
the more hydrophilic sulfenic or sulﬁnic oxidised forms [28] favouring the monomeric form and mimicking
the effect of the more hydrophilic C326S mutant. The bimodal distribution of the gel ﬁltration traces (Figure 9)
suggests that M2PYK exists predominantly as either monomer or tetramer; however, the broad saddle region
between the peaks could ﬁt with a smaller population of the dimer that may show some enzymatic activity.
To further characterise the M2PYK C326S and C358S point mutants, their enzymatic activity was measured
using the LDH-coupled assay and compared with that of M1- and M2PYK WT (Figures 10 and 11). Despite
Figure 9. Oligomerisation states of WT M2PYK and mutants.
Proteins were incubated at 0.1 mg/ml in PBS-CM at room temperature for 12 h. Analytical gel ﬁltration was carried out to
determine the tetramer (left peaks): monomer (right peaks) ratio with a Superdex® 200 PC 3.2/30 gel ﬁltration column.
Twenty-ﬁve microlitres of sample were subjected to the assay each time. Assuming a bimodal tetramer (T) : monomer (M)
distribution, the peak areas correspond to WT (55% T, 45% M), C358S (79% T, 21% M), and C326S (100% M).
Figure 10. Comparisons of enzymatic activity of M1PYK and M2PYK in the absence and presence of F-1,6-BP.
The activity of M2PYK C326S is much lower than that of other isoforms and mutants. It correlates with the fact that M2PYK
C326S is a monomeric form of pyruvate kinase, which has a very low activity [9]. The effector F-1,6-BP activated M2PYK
C326S, but only to ∼30% of the maximum activity of pyruvate kinase.
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the predominantly monomeric nature of M2PYK C326S, it was found to retain ∼20% of WT activity that was
increased to ∼50% with the addition of the allosteric regulator F-1,6-BP (Figure 10). The activity of M2PYK
C358S was found to be very similar to that of WT both in the absence and presence of F-1,6-BP (Figure 10).
The effect of the point mutations on the activity of M2PYK in oxidising (−DTT) and reducing (+DTT) condi-
tions was also measured (Figure 11). M2PYK C358S shows some protection from oxidising conditions, having
a higher activity than WT in the absence of DTT (Figure 11). The activity of the M2PYK C326S mutant is
increased by the addition of DTT, suggesting that it may not be the only residue that is involved in the regula-
tion of M2PYK by oxidation (Figure 11).
The crystal structure of M2PYK C358S was reﬁned at a resolution of 3.1 Å. Comparison of the B-factors in
the structure reﬁned with cysteine in position 358 and those in the structure reﬁned with serine in position 358
gave a clear indication that the C358S mutation had been crystallised with the serine side chain giving a good
ﬁt with the calculated electron density (Supplementary Table S2). The only other difference between the
M2PYK C358S structure and M2PYK WT is the presence of Mg2+-ATP in the active sites of the C358S struc-
ture, which is not found in the WT structure. Interestingly, no other published human muscle PYK structures
have ATP in the active site, even when crystallised with ATP present. Structural alignment of M2PYK C358S
with the M2PYK WT structure (PDB ID: 3SRD) gives an overall RMS ﬁt of 0.6 Å, indicating that there are no
signiﬁcant differences in backbone conformation. In the WT protein, Cys358 forms van der Waals interactions
with the hydrophobic side chains of I48 and L465 which are lost in the C358S mutant.
S-Nitrosation of M2PYK
The modiﬁcation of cysteine residues by the addition of nitric oxide has emerged as an important regulatory
mechanism in diverse cellular processes with over 2000 nitrosated protein targets identiﬁed, ∼580 of these
protein targets being from human cells [30]. In vivo S-nitrosation of cysteine residues occurs via the addition of
an NO moiety to a rare, highly reactive, protein cysteine thiol to form an S-nitrosothiol [31]. In mammals, NO
is predominantly formed by nitric oxide synthase (NOS), which forms NO as a by-product of the metabolism
of L-arginine to L-citrulline. There are three isoforms of NOS present in mammals; nNOS (predominating in
neuronal tissue), iNOS (inducible in a wide range of cells and tissues), and eNOS (ﬁrst found in vascular endo-
thelial cells) [32]. S-nitrosation has been shown to be involved in many cancer cell phenotypes including cell
growth, apoptosis, invasion, and angiogenesis [33,34].
A proteomics study using rat brain lysates has shown that only a relatively small subset of nitrosated proteins
form stable nitrosothiol derivatives [35]. One of these unexpectedly stable sites was identiﬁed as rat
M2PYKCys326. In a related proteomics study, in which a variety of mouse tissues were tested, PYK was found
to be S-nitrosated [36]. In kidney, lung, liver, and thymus, Cys326 was identiﬁed as the only S-nitrosated cyst-
eine in PYK, while in brain and heart nitrosated Cys326 was identiﬁed along with only one other cysteine
(Cys49). The present study also showed that brain, heart and thymus M2PYK can also be nitrosated in eNOS−/−
mice and therefore does not require eNOS activity for nitrosation.
Figure 11. Effect of DTT on the enzymatic activity of M2PYK WT and mutants.
Enzymatic activity of M2PYK, MPYK C358S and M2PYK C326S in the presence of 1 mM DTT (white) and in the absence of
DTT (grey). Activities are shown relative to M2PYK in the absence of DTT (100%).
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Biotin-switch assay comparing WT, C326S, and C358S M2PYK
We have determined the susceptibility of human PYK to S-nitrosation using the biotin-switch technique as
described in the Experimental Section [37]. Brieﬂy, bacterially expressed, puriﬁed M1- and M2PYK WT pro-
teins were treated with freshly prepared CysNO, followed by denaturation of the protein and blocking of the
unnitrosated cysteines with methylmethanethiosulfonate (MMTS). The nitroso moieties were then removed by
treatment with ascorbate and replaced with biotin by the addition of biotin-HPDP. The biotinylated proteins
were then analysed by SDS–PAGE and western blot with anti-biotin antibody (Figure 12). The results show
that both M1- and M2PYK are S-nitrosated, with M2PYK being S-nitrosated to a greater extent than M1PYK
(Figure 12).
To examine the role played by C326 and C358, the biotin-switch technique was carried out with M2PYK
WT, and the M2PYK mutants C326S and C358S following a slightly modiﬁed protocol. The M2PYK proteins
were treated with freshly prepared CysNO followed by denaturation of the protein and blocking of the unnitro-
sated cysteines with NEM. Ascorbate was then added to remove the nitroso moieties and the resulting free sulf-
hydryl groups reacted with biotin-HPDP. The biotinylated protein was then captured on streptavidin beads,
eluted with β-mercaptoethanol, and analysed by SDS–PAGE and western blot with anti-His antibody. Analysis
of the M2PYK C326S mutant by the biotin-switch technique shows that removing this cysteine almost com-
pletely eliminates the S-nitrosation of M2PYK (Figure 13). For comparison, the M2PYK C358S mutant was
also analysed and resulted in a signal similar to the WT protein (Figure 13), showing that C326 is more prone
to modiﬁcation than C358.
Nitrosation of M2PYK is decreased when the tetrameric form is stabilised
As Cys326 is buried in the A–A interface, we hypothesised that S-nitrosation of this cysteine would be inhibited
when M2PYK was stabilised in the tetrameric state. To test this, we incubated M2PYK with F-1,6-BP and
Figure 12. In vitro biotin-switch assay shows that M2PYK is more susceptible to nitrosation than M1PYK.
SDS–PAGE (bottom) and anti-biotin western blot (top) of biotinylated M1PYK and M2PYK. Bacterially expressed, puriﬁed
M1PYK, and M2PYK WT proteins were treated with freshly prepared CysNO (M1+ and M2+) or without CysNO (M1− and M2−).
This was followed by denaturation of the protein and blocking of the unnitrosated cysteines with MMTS. Treatment with ascorbate
was used to remove the nitroso moieties, which were then replaced with biotin by the addition of biotin-HPDP.
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phenylalanine, which have been shown to stabilise M2PYK in the tetrameric form [10]. The intensity of the
western blot bands for ‘tetramer-stabilised’ M2PYK treated with Phe and F-1,6-BP shows a marked decrease,
consistent with Cys326 being protected from S-nitrosation. These results are consistent with the published pro-
teomics studies [34] and suggest that the major target of S-nitrosation in M2PYK is Cys326. A consequence of
nitrosation or oxidation of this residue, which lies in the A–A interface (Figure 1), will be a shift in equilibrium
towards inactive monomer formation.
Summary and conclusion
Our results show that the difference in the effect of oxidising conditions on the enzymatic activities of M1 and
M2 isoforms may be explained by the difference in their oligomeric states. M1PYK is tetrameric, whereas
M2PYK is found in an equilibrium between tetramer, dimer, and monomer [9,10]. The continuous dissociation
and re-association of the M2PYK monomers exposes Cys326 to oxidising conditions. Oxidation (by ROS or
RNS) of Cys326 by a sulfenic or nitroso group will hinder the (re)forming of the active tetramer, thus decreas-
ing the activity of the enzyme until the cytosol has sufﬁcient reducing power. In contrast, the cysteines of
M1PYK, which are protected within a much more stable tetramer, are less exposed to oxidising conditions.
M2PYK is a highly regulated allosteric enzyme which has already been shown to be affected by many small
molecules as well as post-translational modiﬁcations such as phosphorylation, acetylation, and cysteine oxida-
tion. We show here that oxidising conditions regulate the activity of M2PYK by pushing the oligomeric equilib-
rium towards the inactive monomeric form thereby reducing enzymatic activity. M2PYK has been implicated
in the control of intracellular ROS that are increased in cancer cells compared with healthy cells [23]. It has
been proposed that inhibition of M2PYK leads to accumulation of the glycolytic intermediate glucose 6-
phosphate, which then feeds into the PPP generating the NADPH required by the enzyme GR to generate
GSH for ROS detoxiﬁcation [23]. Owing to the reversible nature of cysteine oxidation, once sufﬁcient GSH has
been produced to reduce the oxidised cysteines, the activity of M2PYK would be restored. In this way, M2PYK
has the potential to act as a redox sensor preventing the toxic build-up of ROS or RNS in all proliferating cells,
including fast growing tumours.
We also show that the effects of amino acid activators (Ser and His) and inhibitors (Ala, Phe, and Trp) are
also modulated by the redox state of M2PYK adding another level of sophistication to the regulatory messages
that can be processed. The term ‘allostatic regulator’ has been used to describe how many different stress and
metabolic signals are combined to provide a best or most appropriate enzymatic output dependent on the
current status of the cell [10]. M2PYK can sense levels from a wide range of signals including stress induced by
RNS or ROS, cellular concentrations of activating metabolites (Ser, F-1,6-BP), and levels of inhibitory amino
acids (Phe, Ala, and Trp). Each of these factors affects enzymatic activity by altering the conformational or oli-
gomeric state of M2PYK. Importantly, it is not the absolute level of each of these various signals, but the rela-
tive amounts that will determine how efﬁciently M2PYK will produce pyruvate and ATP and provide the cell
with an ‘allostatic response’ [10] to a changed cellular environment.
Figure 13. S-nitrosation of M2PYK mutants and ligand complexes.
(A) S-nitrosation of M2PYK WT and mutants. The intensity of western blot bands reﬂects the degree of S-nitrosation. The
negative control (−) is a protein that was not S-nitrosated. The positive control (+) is done with an unfolded protein (exposing all
cysteines to S-nitrosation). The level of nitrosation is signiﬁcantly reduced in the C326S mutant. (B) S-nitrosation M2PYK is
affected by modulators. The intensity of western blot bands reﬂects the degree of S-nitrosation. M2PYK complexes with FBP
and Phe stabilise M2PYK in a tetrameric state and reduce the amount of nitrosation. The negative control (−) is a protein that
was not S-nitrosated.
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